Boundless Bio

At the annual general meeting, James Christensen and Jennifer Lew were elected as Class II directors; both seats run until the 2029 annual meeting. Shareholders confirmed KPMG as the independent auditor for the fiscal year ending December 31, 2026. Boundless Bio presented preclinical data on BBI‑940 and identified a kinesin target protein as a promising approach. The company also announced the early termination of its San Diego lease and will pay a lease amendment/termination fee of $10 million; the security deposit of about $0.5 million will be retained. » Más en de.investing.com

At the AACR annual meeting Boundless Bio presented preclinical data on BBI-940, an orally administered kinesin degrader that disrupts segregation of extrachromosomal DNA (ecDNA) in cancer cells. Studies showed that degradation of the target protein leads to missegregation, depletion of ecDNA and reduced viability of ecDNA-containing cancer cells; in vivo models demonstrated tumor regressions and antitumor activity in breast cancer models. BBI-940 is currently being evaluated in the phase 1 KOMODO-1 study in patients with advanced ER+/HER2- and TNBC-LAR. The company is focusing on ecDNA-driven tumors; the report also briefly mentioned the stock and financial metrics. » Más en de.investing.com

Boundless Bio terminated the lease for about 80,168 sq ft of lab and office space in San Diego early, effective May 31, 2026, and will pay the landlord a $10 million settlement; the posted security deposit of about $0.5 million will be retained. The termination became effective after a replacement tenant was found and is intended to ease the company’s liquidity. Additionally, Boundless Bio reported better‑than‑expected Q4 results of -$0.58 per share, launched the KOMODO‑1 Phase‑1 study for BBI‑940, and is targeting proof‑of‑concept by the second half of 2028; Leerink confirms. » Más en de.investing.com